Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8\(^+\) T Cells


Department of Paediatrics, University of Oxford, United Kingdom; Vaccine & Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, USA; Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London, United Kingdom; Department of Sexual Health, Royal Berkshire Hospital, Reading, United Kingdom; Centre for AIDS Research, Kumamoto University, Kumamoto, Japan; Departments of Medicine and Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, USA; AIDS Research Institute IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

CD8\(^+\) T cells are major players in antiviral immunity against human immunodeficiency virus type 1 (HIV-1) through recognition of viral epitopes presented on the surface of infected cells. However, the early events involving HIV-1 epitope presentation to CD8\(^+\) T cells remain poorly understood but are nonetheless crucial for the rapid clearance of virus-infected cells. Here, we comprehensively studied the kinetics of antigen presentation of two protective epitopes, KF11Gag and KK10Gag, restricted by HLA alleles B*57:01 and B*27:05, respectively, and compared these to KY9Pol and VL9Vpr epitopes in a single cycle of HIV-1 replication. We consistently demonstrate differences in epitope presentation kinetics, with very early presentation, within 3 h postinfection, for the protective KF11Gag, KK10Gag epitopes, and KY9Pol but only late presentation for VL9Vpr. We show that this early presentation relies on the antigen being presented from incoming viral particles and is correlated with rapid CD8\(^+\) T cell activation and clearance of virus-infected cells. Additionally, our data indicate a dose-response dependency between the levels of CD8\(^+\) T cell activation and the amount of virus inoculum. These data reflect a proof of principle emphasizing the importance of identifying early-presented viral epitopes for rapid elimination of HIV-1-infected cells.

CD8\(^+\) T cells are an important component of the adaptive immune system with a crucial function in controlling intracellular pathogens. CD8\(^+\) T cells recognize pathogen-derived peptides in the context of HLA class I molecules on the surface of infected cells to mediate their killing. In the last decade, much effort has focused on the design of vaccines that aim to control intracellular pathogens such as human immunodeficiency virus type 1 (HIV-1) through the induction of potent CD8\(^+\) T cell responses (1, 2). The attempt to design CD8\(^+\) T cell-mediated vaccines against HIV-1 is based on strong evidence supporting the role of CD8\(^+\) T cell responses in the control of virus replication (3). Various studies suggest that host genetic traits, such as the expression of certain HLA class I molecules, are related to HIV-1 control (4–6). Additionally, HIV-1 Gag targeting (7), virus immune escape facilitating virus attenuation (8, 9), and the quality of the CD8\(^+\) T cell responses have been independently linked to HIV-1 immune control (10–13).

However, a common limitation for the characterization of CD8\(^+\) T cell responses is the use of artificial exogenous peptides in functional assays, such as enzyme-linked immunospot assay (ELISpot), to determine the breadth and magnitude of CD8\(^+\) T cell responses. Recognition of exogenous peptides by CD8\(^+\) T cells in these assays does not necessarily reflect true antiviral activity through recognition of HIV-1-infected cells displaying endogenously processed peptides (14). Two reasons for this are that the antigen-processing machinery within infected cells is bypassed and that peptides in such assays are used at nonphysiological concentrations. Alternative approaches, such as those involving the use of HIV-1-infected cells (15–17), provide additional information related to direct CD8\(^+\) T cell-mediated antiviral activity and the kinetics of epitope presentation.

In recent years, various studies have demonstrated the importance of epitope presentation timing for subsequent clearance of virus-infected cells. However, these studies were mainly carried out in the simian immunodeficiency virus (SIV) model (18–21) and the majority of studies on HIV-1 have not focused on a single cycle of virus replication (22, 23). Consequently, despite the large number of HIV-1 epitopes described to date, very little is known about the early events of epitope presentation and their contribution to rapid clearance of virus-infected cells. We recently developed an in vitro model system to examine anti-HIV-1 CD8\(^+\) T cell activity mediated by presentation of various viral epitopes (24). In the present work, we used this experimental approach to further assess, in various cell types, the kinetics and mechanisms underlying early antigen presentation. For this purpose, we focused on two important immunodominant HIV-1 epitopes, KF11Gag and KK10Gag, restricted by HLA-B*57:01 and HLA-B*27:05, respectively, known to be involved in superior in vivo viral control (7, 8, 25–28). We compared these with two epitopes, KY9Pol and...
VLPs, restricted by HLA-B*27:05 and generated pure HIV-1-specific CD8+ T cell lines to define the kinetics of epitope presentation. In addition, we refined our previous model to demonstrate the role of incoming viral particles to deliver early epitope presentation and killing of virus-infected cells and to underline once again, the importance of using virus-infected cells for in vitro models in order to characterize activity of HIV-1-specific CD8+ T cells.

MATERIALS AND METHODS

Study subjects. Patient material for in vitro assays was derived from 2 treatment-naive individuals with chronic HIV-1 infection. Patients were HLA typed as described in reference 7 and recruited from a local cohort of treatment-naive HIV-1-infected individuals in England. Clinical data and HIV CD8+--specific responses measured by ELISPOT assay are included in Table 1. Informed consent was obtained from the participating individuals. The institutional review board at the University of Oxford approved the study.

Cell lines. To assess epitope presentation of HLA-B*27:05-restricted epitopes, the HIV-1- permissive U937 cell line transfected with the HLA-B*27:05 gene was used as target cells (24). The HLA-B*57:01-restricted KF11Gag epitope was assessed using the H9 T cell clone transduced with HLA-B*57:01. HLA-mismatched CD4+ cell lines were either U937, H9, or the human lymphoblastoid NK target cell line .221, expressing CD4+ and either HLA-B*1503 or HLA-B*1510 (29). All cells were cultured in RPMI medium with 10% fetal calf serum (FCS) (HyClone), L-glutamine, penicillin, and streptomycin (R10). Selection antibiotic geneticin or kanamycin was added to R10 culture medium for U937 and .221 cell lines, respectively. Primary CD4+ T cells were freshly isolated human peripheral blood mononuclear cells (PBMCs), which were subsequently activated using phytohemagglutinin (PHA) (10 μg/ml) and staphylococcus enterotoxin B (1 μg/ml) (SEB) for 4 days, cultured in R10. Specific CD8+ T cell lines were generated as described previously (24).

Virus and virus-like particle (VLP) production. Viral stocks were produced by cotransfection in MT4 cells of p83-2 and p83-10eGFP plasmids derived from NL4-3 plasmid as previously described (30, 31). Virus was harvested and stored at −80°C, and the 50% tissue culture infective dose (TCID50) for each viral stock was determined in MT4 cells using the Reed and Muench method.

HIV-1 GFP VLPs (HIV-VLPs) pseudotyped with the vesicular stomatitis virus G (VSV-G) protein envelope were produced by transfecting the HIV-1 packaging plasmid pCMVΔR8.2 (which encodes all HIV-1 proteins except gp160 envelope protein) (32), the green fluorescent protein (GFP)-encoding vector genome pCGW (which does not encode any HIV-1 proteins) (33), and the VSV-G-encoding plasmid pMDG (34) into 293T cells using Fugene-6 (Roche), as previously described (35). The supernatant contained virosions consisting of all the normal components of HIV-1 particles including Gag, Pol, and Vpr with the natural HIV-1 envelope protein replaced with the VSV-G envelope protein. Because the packaged genome inside the VLP does not encode HIV-1 proteins, then VLP-infected cells express only GFP and cannot synthesize any viral proteins. Therefore, all viral proteins inside the infected cell are derived from incoming VLPs and not from de novo protein transcription. Supernatant from transfected 293T cells was purified by ultracentrifugation through a 20% sucrose cushion. The HIV-VLP dose was measured by reverse transcriptase (RT) enzyme-linked immunosorbent assay (ELISA) (Roche) according to the manufacturer’s instructions. The functional titer of HIV-VLP was determined on GHOST cells, where 1 ng RT is equivalent to 2 × 10⁸ infectious units (35). In the experiments described, a multiplicity of infection (MOI) of 1 based on the GHOST titer gives an MOI of around 0.2 on B cell line (BCL) cells and an MOI of 1 on U937 cells due to differences in cell permissiveness to infection (data not shown). Sequences of Gag, Pol, and Vpr epitopes are identical in plasmids pCMVΔR8.2 and p83-2, used to generate VLP and HIV, respectively. Both plasmids are derived from NL4.3 GenBank accession code M19921 and carry the optimal epitope sequence defined in the Los Alamos Immunology database and used to grow the specific CD8+ T cell lines (Table 2).
scattered live cells and analyzed in a CD4<sup>+</sup> versus p24-PE or CD4<sup>+</sup> versus GFP-fluorescein isothiocyanate (FITC) double dot plot. All samples were analyzed using FlowJo software V8.8.6 (Tree Star, Inc.). Killing efficiencies were calculated as follows: (% p24<sup>+</sup> or GFP<sup>+</sup> CD4<sup>+</sup> cocultured with specific CD8<sup>+</sup> T cells)/(% p24<sup>+</sup> or GFP<sup>+</sup> CD4<sup>+</sup> without any CD8<sup>+</sup> T cells) × 100.

**TcR affinity and polyfunctionality.** The functional avidity and polyfunctionality of epitope-specific CD8<sup>+</sup> T cells were investigated by intracellular cytokine staining (ICS) assay using a multiparameter antibody panel. Log<sub>10</sub> serial peptide titrations pulsed on an HLA-matched B cell line were cocultured for 3 h with HIV-1-specific CD8<sup>+</sup> T cell lines in the presence of brefeldin A and GolgiStop followed by staining of CD8<sup>+</sup>, HLA-B<sup>+</sup>, and IFN-γ expression gated on CD8<sup>+</sup> T cells that resulted in ≥50% maximum (50% inhibition concentration [IC<sub>50</sub>]) using GraphPad Prism V5.0a. Functional assessments of simultaneous expression of CD107a, MIP1β, and IFN-γ for comparison of effector marker profiles were analyzed using FlowJo V8.8.6.

### RESULTS

**KF11Gag, KK10Gag, and KY9Pol HIV-1-derived CD8<sup>+</sup> T cell epitopes are presented early after infection of CD4<sup>+</sup> T cells.** To investigate the kinetics of epitope processing and presentation in CD4<sup>+</sup> T cells following HIV-1 infection, we first focused on the CD8<sup>+</sup> T cell epitope restricted by HLA-B<sup>+</sup>57:01, KF11Gag, which is associated in vivo with control of HIV-1 (7, 8, 25). Pure CD8<sup>+</sup> T cell lines to >95% specificity for KF11Gag were generated (Table 1). To ensure synchronous infection of target cells, we adopted the previously described “magnetofection” method (36). Subsequently, we cocultured KF11Gag-specific CD8<sup>+</sup> T cells in two different HIV-1-infected cell types expressing HLA-B<sup>+</sup>57:01, H9 cells transduced with HLA-B<sup>+</sup>57:01, and primary CD4<sup>+</sup> T cells. In order to determine the background levels of potential nonspecific activation of the CD8<sup>+</sup> T cell lines tested (independent of viral infection and epitope presentation), we infected HLA-mismatched cells and cocultured them with each of the CD8<sup>+</sup> T cells used in the experiments. No nonspecific activation was observed in any of the background controls (Fig. 1C and D). Additionally, similar levels of HIV-1-infected cells were measured at the beginning of the experiment for the HLA-matched and mismatched CD4<sup>+</sup> T cell lines. Therefore, differences in activation between those cell types could not be attributed to variations in the amount of incoming viral particles available for antigen processing and presentation.

For all experiments, the readout of epitope presentation was dual staining of CD107a and MIP1β in CD8<sup>+</sup> T cell lines, since these markers have been previously shown to be crucial for CD8<sup>+</sup> T cell antiviral activity (7) and in our hands are the most sensitive markers for activation of HIV-specific CD8<sup>+</sup> T cell lines in these assays (Fig. 1A).

We first showed that KF11Gag-specific CD8<sup>+</sup> T cells are activated by HIV-infected HLA-matched targets within 3 h of infection (Fig. 1A). We controlled for the expression of HLA-B<sup>+</sup>57:01 and the KF11Gag specificity by peptide pulsing matched CD4<sup>+</sup> T cells (Fig. 1B). We observed a two-phase kinetics of epitope presentation in both H9 and primary CD4<sup>+</sup> T cells for KF11Gag with early presentation at 3 to 6 h followed by a boost of activation at 18 h postinfection (Fig. 1C).

To compare the kinetics of antigen presentation of KF11Gag with those of other HIV-1-specific epitopes associated with control of viremia, we generated pure CD8<sup>+</sup> T cell lines for the HLA-B<sup>+</sup>27:05-restricted KK10Gag and included two additional epitopes, KY9Pol and VL9Vpr, also restricted by HLA-B<sup>+</sup>27:05 for comparison (Table 2). Using the same experimental approach, we observed a similar two-phase kinetics of early epitope presentation for the KK10Gag and KY9Pol epitopes (3 to 6 h), with a second wave of activation between 18 and 24 h (Fig. 1D). In contrast, the VL9Vpr epitope showed a marked difference in presentation kinetics, with partial CD8<sup>+</sup> T cell activation only at later time points. Thus, these data demonstrate comparable kinetics of early presentation for KF11Gag and KK10Gag protective epitopes together with KY9Pol, in contrast to the VL9Vpr epitope, which is recognized only at later time points.

**Early kinetics of epitope presentation rely on antigen processing in the absence of virus replication.** The early presentation kinetics for KF11Gag, KK10Gag, and KY9Pol epitopes suggest that activation of specific CD8<sup>+</sup> T cells do not depend on de novo synthesis of viral protein to access the class I processing pathway. In order to establish unequivocally the contribution from incoming HIV-1 particles to the kinetics of early epitope presentation, we developed a single-cycle infection system based on pseu-

### Table 2 HIV-specific CD8<sup>+</sup> T cell lines and viral vectors used in the study

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>HLA restriction allele</th>
<th>Epitope</th>
<th>Protein</th>
<th>Amino acid position in HXB2</th>
<th>Viral vector</th>
<th>HIV clade B sequence</th>
<th>% CD8&lt;sup&gt;+&lt;/sup&gt; T cell line specificity&lt;sup&gt;a,b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>R039</td>
<td>HLA-B*57:01</td>
<td>KF11</td>
<td>Gag</td>
<td>162–172</td>
<td>Seq database&lt;sup&gt;a&lt;/sup&gt;</td>
<td>KAF5PEV1MPF</td>
<td>98.4</td>
</tr>
<tr>
<td>R039</td>
<td>HLA-B*27:05</td>
<td>KK10</td>
<td>Gag</td>
<td>263–272</td>
<td>NL4-3</td>
<td>pCMVΔAR8.2</td>
<td>99.6</td>
</tr>
<tr>
<td>R039</td>
<td>HLA-B*27:05</td>
<td>KY9</td>
<td>Pol</td>
<td>186–194</td>
<td>Seq database</td>
<td>pCMVΔAR8.2</td>
<td>99.4</td>
</tr>
<tr>
<td>R035</td>
<td>HLA-B*27:05</td>
<td>VL9</td>
<td>Vpr</td>
<td>31–39</td>
<td>Seq database</td>
<td>pCMVΔAR8.2</td>
<td>99.4</td>
</tr>
</tbody>
</table>

<sup>a</sup> Seq database, Los Alamos Immunology database (http://www.lanl.gov).

<sup>b</sup> Tetramer-positive CD3<sup>+</sup> CD8<sup>+</sup> gated T cells.
dotyped HIV-1 VLPs encoding GFP. The VLPs encode GFP rather than viral proteins, and therefore infected cells become green but cannot express any viral proteins. In this way, we can monitor virus infection by the expression of GFP in the target cells (Fig. 2).

Thus, we used HIV-VLP to infect a B cell line expressing both HLA-B*27:05 and HLA-B*57:01. We observed early presentation and similar kinetics for both KF11Gag- and KK10Gag-specific CD8\(^+\) T cell activation in the absence of HIV-1 protein transcription (Fig. 3A and B). In addition, the KY9Pol-specific CD8\(^+\) T cells were also activated within the same time, although no increase in activation was detected over time (Fig. 3B). In contrast, the VL9Vpr-specific CD8\(^+\) T cells did not see any cognate antigen presented from the HIV-VLP infection and sustained dependency on the de novo synthesis of proteins for VL9Vpr epitope presentation.

Once we established the role of incoming viral particles in early epitope presentation for both KF11Gag and KK10Gag in BCL, we confirmed our results using HIV-VLP in an alternative target cell line (U937 expressing CD4\(^+\)) for the HLA-B*27:05-restricted epitopes. In agreement with previous data, we found a similar hierarchy of antigen presentation for all epitopes tested (Fig. 3C and D). Remarkably, both the KK10Gag- and KY9Pol-specific CD8\(^+\) T cell lines reached a peak of activation (5 to 8 h in the case of KK10 Gag and 8 to 20 h for KY9Pol), which additionally supports that, in the absence of virus replication, activation occurs only when cognate antigen is available for the CD8\(^+\) T cells as confirmed by the results for VL9Vpr epitope. To further validate our results, we conducted a similar experiment using fully competent HIV-1 in U937 and primary CD4\(^+\) T cells expressing HLA-B*27:05 as target cells in the presence of an HIV-1 reverse transcriptase inhibitor (AZT), which results in the suppression of HIV-1 protein transcription. We obtained similar findings with KK10Gag and KY9Pol presentation but no VL9Vpr epitope presentation at 24 h postinfection (Fig. 4A and B). Decreased antigen presentation was unrelated to potential cellular toxicity mediated by AZT treatment (Fig. 4C and D). Of note, although the HIV-1 epitope hierarchy was maintained between cell lines, we observed a divergence in the dynamics of antigen presentation.
with the use of either the BCL or the U937 cells. Thus, the faster kinetics found for the U937 cells could be related to the monocytic origin of the cells and their specialization as antigen-presenting cells.

The use of the HIV-VLP system provides clear evidence that the KF11Gag, KK10Gag, and KY9Pol epitope presentation kinetics depend on preformed protein derived from incoming viral particles in the absence of virus replication, whereas VL9Vpr epitope presentation appears to be entirely dependent on the de novo synthesis of protein.

Early presentation of HIV-1 epitopes is associated with early killing of virus-infected cells but is independent of TcR affinity. The early activation of KK10Gag- and KY9Pol-specific CD8\(^+\) T cells is related to early epitope presentation, but whether or not differences in CD8\(^+\) T cell activation over time translate directly into differences in functional killing of HIV-1-infected cells has not been clearly established. Therefore, we investigated the ability of KK10Gag-, KY9Pol-, and VL9Vpr-specific CD8\(^+\) T cells to eliminate virus-infected cells by measuring the reduction of p24-corelated cells, using the same HIV-VLP experimental model. We observed a rapid elimination (>50%) of p24\(^+\)/CD4\(^+\) cells at 5 h and almost complete elimination (>85%) at 20 h postinfection for KK10Gag- and KY9Pol-specific CD8\(^+\) T cells (Fig. 5A and B). In contrast, the VL9Vpr-specific CD8\(^+\) T cells did not exhibit any killing activity, consistent with the lack of CD8\(^+\) T cell activation. We confirmed these observations by measuring the frequency of GFP\(^+\) cells within HIV-VLP-infected cells (Fig. 5C and D). By simultaneous assaying of CD8\(^+\) T cell activity and clearance of virus-infected cells, we demonstrate a direct causality between early activation of KK10Gag- and KY9Pol-specific CD8\(^+\) T cells and early elimination of virus-infected cells (Fig. 5E).

Total HIV-1-specific CD8\(^+\) T cell activation and functionality depend on the amount of antigen presented on virus-infected cells. The discrepancies found in the levels of CD8\(^+\) T cell activation between various HIV-1 epitopes suggest that activation is dependent on the amount of epitope presented on the surface of infected cells. Additionally, cytokine activation...
profiles of CD8\(^+\) T cells through HIV-1-infected cells may differ from the profiles obtained in exogenous peptide-loaded experiments. To test the relationship between the levels of antigen presented and the levels of CD8\(^+\) T cell activation, we infected the U937 CD4\(^-\)/H11001 cells with HIV-VLP at MOI of 1 and 0.1 and measured the subsequent CD8\(^+\)/H11001 T cell activation in each case. A 10-fold decrease in the amount of virus inoculum resulted in a 2- to 3-fold decrease in the percentage of activated CD8\(^+\)/H11001 T cells (Fig. 7A and B). These data suggest a dose-response dependency between the amount of virus inoculum and the level of CD8\(^+\)/H11001 T cell activation. Throughout the study, we have consistently observed a reduction in activation levels of CD8\(^+\)/H11001 T cells in recognition of virus-infected cells compared to exogenous loaded peptides (20% versus 90%). Therefore, we compared the differences between CD8\(^+\)/H11001 T cell activation stimulated by direct exogenous peptide loading and that stimulated by intracellular processed epitopes after HIV-VLP infection (Fig. 7C). It is clear that exogenous-peptide-pulsed BCLs result in a higher magnitude of total CD8\(^+\)/H11001 T cell activation and a more polyfunctional profile of cytokine secretion for all epitopes tested compared to intracellular processed epitopes (median, 90% versus 24%; \(P<0.03\); data not shown). We can estimate that the use of peptide concentrations in the range of 10\(^{-6}\) M in conventional in vitro stimulation assays (38, 39) may be 10\(^3\) to 10\(^5\) times higher than the actual amount of intracellular presented epitopes within infected cells based on the levels of CD8\(^+\) T cell activation (40). These data suggest that most in vitro peptide pulsing studies use nonphysiological concentrations of artificial peptides, which may mask differences between the total activation and polyfunctionality of CD8\(^+\) T cells and those of virus-infected cells.

**DISCUSSION**

This study characterizes the properties in terms of the timing of epitope presentation of two HLA class I-restricted epitopes, KF11Gag and KK10Gag, which are known to play a protective role in HIV-1 immune control (7–9, 25, 26, 28). Our data reveal early antigen presentation within 3 to 6 h after HIV-1 infection, well before virus integration and the de novo synthesis of viral proteins (41) for protective KF11Gag and KK10Gag epitopes. The early kinetics also applied to a dominantly targeted KY9Pol epitope (24) but was in contrast to the VL9Vpr epitope, which was presented only at the very late stage of the viral replication cycle.

Consistently, our experiments demonstrate two-phase kinetics of epitope presentation in both primary and immortalized cell lines. We observe a first wave of CD8\(^+\) T cell activation at 3 to 6 h after infection followed by a boost of activation at 18 to 24 h. Based on our results, early CD8\(^+\) T cell activation for KF11Gag, KK10Gag, and KY9Pol epitopes is related to antigen presentation derived from incoming viral particles in the absence of virus replication as demonstrated by the use of HIV-VLP and supported by previous studies (42–44). Meanwhile, the second wave of epitope presentation is presumably related to viral protein synthesis and...
may be linked to the defective ribosomal product (DRiP) pathway (45). This pathway leads to the formation of DRiPs from de novo proteins as substrates for the proteosome to improve class I presentation (46). As a consequence, the DRiP pathway will enhance presentation of epitopes from smaller viral proteins to overcome the threshold for epitope presentation as observed for the VL9Vpr epitope.

There are very limited data regarding the early events in the kinetics of antigen presentation for HIV-1 epitopes. Early antigen presentation has been previously shown for several SIV epitopes (19, 20). However, these results cannot be completely extrapolated to HIV-1 epitopes. Additionally, although various antigen presentation studies have been carried out for HIV-1 (22, 23), their readouts are not based on a single cycle of virus replication and rely on a unique target cell line. Thus, our work overcomes the limitations of previous studies by monitoring the kinetics of epitope presentation during a single cycle of HIV-1 replication and testing the consistency of our results in various cell types.

The early kinetics of peptide presentation do not on their own determine immunodominance. The kinetics of antigen presentation may be important in potentially having an impact on the effectiveness of certain HIV-specific CD8+ T cell responses, since the earlier the recognition, the more likely it is that the cell will be killed before the release of new virions and the less likely that the CD8+ T cells will be affected by Nef-mediated class I downregulation. Thus, whether the immunodominant CD8+ T cell response is one that acts early or late following virus infection of target cells may be critically important in shaping the effectiveness of the anti-HIV CD8+ T cell response in different individuals.

In recent years, multiple studies associated Gag-specific CD8+ T cell responses with improved virus immune control (7, 16, 47). This is consistent with our findings of early presentation and killing of infected cells mediated by KF11Gag and KK10Gag protective epitopes. However, it should be pointed out that this is not the case for all Gag epitopes (21), and early presentation of certain epitopes within the small viral proteins has been previously described, in particular with examples from Nef, Rev, and Vpr epitopes being presented early as a result of being virion associated and prior to de novo synthesis of these proteins (18, 48–50). Therefore, these data suggest that epitope presentation does not depend

FIG 5 KK10Gag- and KY9Pol-specific CD8+ T cells kill virus-infected cells early after infection. Fluorescence-activated cell sorting (FACS) dot plots showing intracellular p24 staining of HLA-B*27:05-positive U937 CD4+ cells after HIV-VLP infection gated on uninfected cells and cocultured with no CD8+ or KK10Gag-, KY9Pol-, or VL9Vpr-specific or mismatched CD8+ T cells shown at 8 h (A) or plotted for all 5 time points as the percentages of CD4+ T cells expressing p24 relative to cells without CD8+ T cells added (mean values and standard errors of the means [SEM] from triplicates (B). (C and D) Gag-, Pol-, and Vpr-specific CD8+ T cell killing monitored by GFP expression in virus-infected cells. FACS plots showing GFP-expressing HLA-B*27:05-positive U937 CD4+ cells after HIV-VLP infection controlled by uninfected cells and cocultured with no CD8+ or KK10Gag-, KY9Pol-, or VL9Vpr-specific or mismatched CD8+ T cells shown at 20 h postinfection (C) and plotted for two time points as mean values and SEM of triplicates (D). (E) Data from panel B were plotted on the left y axis; the percentage of maximum CD8+ T cell activation (CD107a/MIP1β) was plotted on the right y axis; data are shown for the three individual CD8+ T cell lines as mean values and SEM from triplicates.
on HIV-1 protein specificity exclusively but also on epitope properties (49) as well as other antigen-processing factors (51, 52). For example, the special feature of improved stability between dibasic N-terminal peptides for HLA-B*27:05 may result in KK10Gag and KY9Pol epitopes being more stable in the cytosol than VL9Vpr (53).

In addition, the protein-specific source from which the epitope is derived may have an important role in driving an uneven balance in antigen presentation. Epitopes derived from more-abundant viral proteins, such as Gag, which accounts for one-half of the mass in the viral particle (54), may be an initial advantage over smaller proteins to compete for class I processing machinery immediately after viral entry, further increased by posttranscriptional Gag ubiquitination (46). Early antigen presentation kinetics of important Gag epitopes KF11Gag and KK10Gag further help to explain the dominant and protective role of CD8+ T cell responses against these epitopes (7–9, 25, 26, 28), in which early presentation before HLA-I downregulation (48) contributes to rapid CD8+ T cell activation. As a result, early presentation of KF11Gag, KK10Gag, or KY9Pol epitopes contributes to eliminate virus-infected cells before the de novo production of infectious viral particles, preventing new rounds of infection and virus spread.

It may be argued that our experiments could be biased by an abnormally high number of virus-infected cells, as these experiments were performed at MOI between 0.2 and 1 depending on the cell type used, and therefore this infectious dose is expected to be of a magnitude similar to that found in vivo or in cell-to-cell transmission events (55). However, our study has a few limitations. First, it is important to note the limitation of using VSV-G pseudotyped virus that may differ in viral entry mechanisms from HIV-1, using receptor-mediated pH-independent cell membrane fusion, and from HIV-VLP, using a pH-dependent endocytic pathway to access the class I presentation pathway (56). However, both mechanisms of virus entrance lead to the release of intact cores to the cytosol, feeding viral antigen into the class I presentation pathway (57), and therefore similar early epitope presentations are consistently seen in HIV-1 and HIV-VLP infections. Second, our data are limited to four HIV specificities (KF11Gag, KK10Gag, KY9Pol, and VL9 Vpr) restricted by HLA-B57:01 and B27:05 and derived from polyclonal TcR clonotypes, and generalized conclusions therefore cannot necessarily be drawn from these results.

In this study, we found a decrease in total CD8+ T cell activation mediated by virus-infected cells compared to that mediated by extracellular peptide-pulsed cells, which suggests that very small amounts of peptides are presented on the surface of HIV-1-infected cells. We determined that standard peptide pulse experiments use 103- to 105-higher peptide concentrations, as previously calculated (40), and likely overestimate the magnitude and functionality of total CD8+ T cell responses. These results further call for a rigorous definition of CD8+ T cell correlates of immune protection (58).

In conclusion, the data presented here are a proof of principle to show how key epitopes, important for HIV-1 immune control, are presented early in the virus life cycle directly from the incoming viral particles, resulting in rapid CD8+ T cell activation and elimination of virus-infected cells. Based on these data, we suggest that dominant targeting of early-presented epitopes may be an important element for a rapid and initial immune control of HIV-1 infection. However, the epitopes studied here cannot necessarily be extrapolated to protein-specific properties, and further studies including additional specificities and additional HLA class

FIG 6 TcR affinities of enriched CD8+ T cells. Fluorescence-activated cell sorting (FACS) plots showing CD107a- and IFN-γ-producing KY9Pol-specific CD8+ T cells after peptide-titrated presentation on HLA-matched B cell line (A) with IC50 curves shown for KF11Gag-, KK10Gag-, KY9Pol-, and VL9Vpr-specific CD8+ T cells (B) and plotted as log EC50 values (C).
I restriction elements are needed before general conclusions may be drawn.

ACKNOWLEDGMENTS

This work was supported by grants CP09/00279 and PI11/00249 by the ISCIII and the HIV Vaccine Catalan Program (HIVACAT program). J.G.P. holds a Miguel Servet Contract (MS09/00279) funded by FIS-ISCIII (Spanish Government). G.J.T. holds a Wellcome Trust Senior fellowship and has funding from the Medical Research Council and the National Institutes of Health UCL/UCLH Comprehensive Biomedical Research Centre.

We thank Paul Bowness (Oxford, United Kingdom) for the HIV-1-permissive U937 cell line transfected with the HLA-B*27:05 gene. We thank study participants and C. J. Molina and E. Adland for strategic support.

We declare that we have no conflicts of interest.

REFERENCES


